Is Erdafitinib a drug that cannot be stopped after long-term use?

Erdafitinib is an oral small molecule tyrosine kinase inhibitor mainly used to treat advanced urothelial carcinoma carrying FGFR gene mutations or fusions. As a targeted therapy drug, erdafitinib can precisely inhibit the growth signals of cancer cells and delay tumor progression. For patients and doctors, whether long-term use of erdafitinib is needed and management issues after discontinuation are matters that need to be paid attention to during the treatment process.

Generally speaking, erdafitinib is a drug that needs to be taken continuously for a long time. In clinical practice, patients usually need to take the drug daily according to the guidance of a doctor and continue to use it until the condition progresses significantly, the side effects of the drug are intolerable, or other conditions make it inappropriate to continue taking the drug. Because erdafitinib continues to inhibit key tumor-driving pathways, discontinuation of the drug may cause tumor cells to reactivate and grow, thereby accelerating disease progression.

However, long-term use of erdafitinib may also bring certain risks of side effects, such as dry eyes, paronychia, hyperphosphatemia, etc. Therefore, it is necessary to regularly monitor the patient's physical condition during treatment and evaluate the safety of the drug. Once serious adverse reactions occur, the doctor will adjust the dose or temporarily stop the medication according to the specific situation, and perform symptomatic treatment or change the treatment plan if necessary.

In general, patients are usually recommended to take erdafitinib for a long time to maintain the therapeutic effect and avoid stopping the drug without authorization. Patients should take medication and monitor under the guidance of professional doctors to ensure maximum tumor control while taking into account physical safety and quality of life. Whether to discontinue medication or not requires comprehensive consideration of changes in condition and drug tolerance, and is left to the doctor's scientific judgment and decision-making.

Reference link:https://www.balversa.com/